ORI is a Chemicals company. Its directors and officers file their transactions with ASX. The last twelve months, up to 18 October 2026, brought 3 filings signed by 3 insiders.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
For context, the typical company on the same exchange (median of 2,530 companies) published 3 filings over the same period, against 3 filings here.
There has been no open-market purchase by an insider of ORI for at least a year.
In the same sector, recent insider purchases at Culp Inc also feature in our signals. These figures are compiled from regulatory filings published by ASX. They describe what insiders did and are not a recommendation.
Analysts rate ORI Strong Buy (bullish), based on 15 analysts. Average price target: A$25.87.
Transparent value + quality ranking, distinct from the insider signal.
FY ended September 2025 · cache
3 of 3 declarations
ORI is a company operating in the chemicals and materials sector. It is listed on the XASX market.
Purchases our model currently ranks for the recommendations list.
All recommendations